Lithium + L-tryptophan compared with amitriptyline in endogenous depression.

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Neuroscience

Background:

• Endogenous depression is a severe mood disorder requiring effective treatment.
• Established treatments like amitriptyline have limitations and side effects.
• Novel therapeutic combinations are needed to improve patient outcomes.

Purpose of the Study:

• To compare the efficacy of lithium plus L-tryptophan versus amitriptyline for treating endogenous depression.
• To evaluate the safety and tolerability of the combined lithium and L-tryptophan regimen.
• To explore the relationship between serum drug concentrations and clinical response.

Main Methods:

• An open-label study involving 43 inpatients diagnosed with endogenous depression.
• Patients were randomized to receive either lithium + L-tryptophan or amitriptyline for four weeks.
• Clinical assessments used the Hamilton rating scale, with serum drug levels monitored weekly.

Main Results:

• Both treatment groups demonstrated significant improvement in depressive symptoms.
• No significant difference in antidepressive efficacy was observed between the lithium + L-tryptophan and amitriptyline groups.
• No significant correlation was found between steady-state serum drug levels and clinical improvement.

Conclusions:

• Lithium combined with L-tryptophan appears to be an effective treatment for endogenous depression.
• This combination therapy presents a viable alternative to standard antidepressants like amitriptyline.
• Further research is warranted to confirm these findings and explore long-term efficacy and safety.